Emerald Advisers LLC Buys Shares of 120,805 CeriBell (NASDAQ:CBLL)

Emerald Advisers LLC purchased a new position in CeriBell (NASDAQ:CBLL) in the fourth quarter, Holdings Channel reports. The fund purchased 120,805 shares of the company’s stock, valued at approximately $3,126,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. PNC Financial Services Group Inc. acquired a new stake in shares of CeriBell in the fourth quarter worth about $47,000. Rhumbline Advisers acquired a new stake in shares of CeriBell in the fourth quarter worth about $320,000. Bank of New York Mellon Corp acquired a new stake in shares of CeriBell in the fourth quarter worth about $628,000. Charles Schwab Investment Management Inc. acquired a new stake in shares of CeriBell in the fourth quarter worth about $2,500,000. Finally, Vanguard Group Inc. acquired a new stake in shares of CeriBell in the fourth quarter worth about $18,015,000.

CeriBell Stock Up 0.7 %

NASDAQ CBLL opened at $20.42 on Monday. CeriBell has a twelve month low of $18.69 and a twelve month high of $32.75. The business’s 50-day simple moving average is $22.35.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Tuesday, February 25th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The business had revenue of $18.53 million during the quarter, compared to analysts’ expectations of $17.55 million. As a group, analysts expect that CeriBell will post -2.46 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $33.00 price target on shares of CeriBell in a research report on Wednesday, February 26th. TD Cowen boosted their price objective on CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a research report on Monday, December 9th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, CeriBell has an average rating of “Buy” and an average target price of $32.60.

CeriBell Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.